Exclusive: Genelux VP Makes Significant Investment in Company Stock
Friday, 7 June 2024, 22:42
Genelux VP of Clinical Trials Invests in Company Stock
In a recent development, the VP of clinical trials at Genelux has made a substantial investment in the company by purchasing stocks worth over $13,000.
This move demonstrates the VP's confidence in Genelux's future and commitment to its success.
Investors are intrigued by this insider activity and are eager to see how it influences Genelux's performance in the market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.